NASDAQ: ABUSArbutus Biopharma Corp Stock Ownership - Who owns Arbutus Biopharma?
Insider buying vs selling
Have Arbutus Biopharma Corp insiders been buying or selling?
Buy
Sell
| Name | Role | Date | Shares | Price | Value |
|---|---|---|---|---|---|
| David C. Hastings | Chief Financial Officer | 2025-02-04 | 22,183 | $3.28 | $72.83kSell |
| Michael J. McElhaugh | Interim President CEO | 2025-02-04 | 23,790 | $3.28 | $78.10kSell |
| J. Christopher Naftzger | General Counsel and CCO | 2025-02-04 | 11,333 | $3.28 | $37.21kSell |
| Karen Sims | Chief Medical Officer | 2025-02-04 | 19,348 | $3.28 | $63.52kSell |
| Keith S. Manchester | Director | 2024-08-14 | 8,846 | $3.69 | $32.63kSell |
| Keith S. Manchester | Director | 2024-08-14 | 54,915 | $0.56 | $30.75kBuy |
ABUS insiders have sold more... subscribe to Premium to read more.
Net Insider Buy/Sell (L12M) Ownership
Be the first to know when ABUS insiders and whales buy or sell their stock.
ABUS Shareholders
What type of owners hold Arbutus Biopharma Corp stock?
Institutional
Insider
Retail
| Name | Hold | Shares | Value | Type |
|---|---|---|---|---|
| Matthew Gline | 20.28% | 38,847,462 | $125.87M | Insider |
| Roivant Sciences Ltd | 20.28% | 38,847,462 | $125.87M | Insider |
| Dexxon Holdings Ltd | 16.72% | 32,027,080 | $103.77M | Insider |
| Morgan Stanley | 12.42% | 23,792,389 | $77.09M | Institution |
| Vivek Ramaswamy | 8.39% | 16,068,455 | $52.06M | Insider |
| Dexcel Pharma Technologies Ltd | 8.36% | 16,013,540 | $51.88M | Insider |
| Viking Global Equities Master Ltd | 8.36% | 16,013,540 | $51.88M | Insider |
| Patrick MacHado | 8.36% | 16,013,540 | $51.88M | Insider |
| Viking Global Investors LP | 8.36% | 16,013,540 | $51.88M | Insider |
| Viking Global Performance LLC | 8.36% | 16,013,540 | $51.88M | Insider |
ABUS vs Biotech Stocks
Arbutus Biopharma Stock Ownership FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.